Abbonarsi

Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: The Studying the Treatment of Acute hyperTension (STAT) Registry - 12/08/11

Doi : 10.1016/j.ahj.2009.07.020 
Jason N. Katz, MD a, Joel M. Gore, MD b, Alpesh Amin, MD c, Frederick A. Anderson, PhD b, Joseph F. Dasta, MSc d, James J. Ferguson, MD e, Kurt Kleinschmidt, MD f, Stephan A. Mayer, MD g, Alan S. Multz, MD h, W. Frank Peacock, MD i, Eric Peterson, MD a, Charles Pollack, MD j, Gene Yong Sung, MD k, Andrew Shorr, MD l, Joseph Varon, MD m, Allison Wyman, MS b, Leigh A. Emery, MS b, Christopher B. Granger, MD a,

on behalf of the STAT Investigators1

  See Appendix B for a complete listing of STAT Investigators.

a Duke Clinical Research Institute, Durham, NC 
b University of Massachusetts Medical School, Worcester, MA 
c UCIMC, Orange, CA 
d University of Texas College of Pharmacy, Dallas, TX 
e The Medicines Company, Parsippany, NJ 
f UT Southwestern Medical Center, Dallas, TX 
g Columbia University Medical Center, New York, NY 
h Albert Einstein College of Medicine, Bronx, New York, NY 
i The Cleveland Clinic, Cleveland, OH 
j Pennsylvania Hospital, Philadelphia, PA 
k University of Southern California, Los Angeles, CA 
l Washington Hospital Center, Washington, DC 
m The University of Texas Health Science Center, Houston, TX 

Reprint requests: Christopher B. Granger, MD, Duke Clinical Research Institute, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705.

Riassunto

Background

Limited data are available on the care of patients with acute severe hypertension requiring hospitalization. We characterized contemporary practice patterns and outcomes for this population.

Methods

STAT is a 25-institution, US registry of consecutive patients with acute severe hypertension (>180 mm Hg systolic and/or >110 mm Hg diastolic; >140 and/or >90 for subarachnoid hemorrhage) treated with intravenous therapy in a critical care setting.

Results

One thousand five hundred eighty-eight patients were enrolled (January 2007 to April 2008). Median age was 58 years (interquartile range 49-70 years), 779 (49%) were women, and 892 (56%) were African American; 27% (n = 425) had a prior admission for acute hypertension and 486 (31%) had chronic kidney disease. Median qualifying blood pressure (BP) was 200 (186, 220) systolic and 110 (93, 123) mm Hg diastolic. Initial intravenous antihypertensive therapies used to control BP varied, with 1,009 (64%) patients requiring multiple drugs. Median time to achieve a systolic BP <160 mm Hg (<140 mm Hg for subarachnoid hemorrhage) was 4.0 (0.8, 12) hours; 893 (60%) had reelevation to >180 (>140 for subarachnoid hemorrhage) after initial control; and 63 (4.0%) developed iatrogenic hypotension. Hospital mortality was 6.9% (n = 109) with an aggregate 90-day mortality rate of 11% (174/1,588); 59% (n = 943) had acute/worsening end-organ dysfunction during hospitalization. The 90-day readmission rate was 37% (523/1,415), of which one quarter (132/523) was due to recurrent acute severe hypertension.

Conclusion

This study highlights heterogeneity in care, BP control, and outcomes of patients hospitalized with acute severe hypertension.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2009  Mosby, Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 158 - N° 4

P. 599 - Ottobre 2009 Ritorno al numero
Articolo precedente Articolo precedente
  • Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: Four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial
  • Emilio Di Lorenzo, Rosario Sauro, Attilio Varricchio, Michele Capasso, Tonino Lanzillo, Fiore Manganelli, Ciro Mariello, Francesco Siano, Maria Rosaria Pagliuca, Giovanni Stanco, Giuseppe Rosato, Giuseppe De Luca
| Articolo seguente Articolo seguente
  • Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis
  • Lawreen H. Connors, Tatiana Prokaeva, Amareth Lim, Roger Théberge, Rodney H. Falk, Gheorghe Doros, Alan Berg, Catherine E. Costello, Carl O'Hara, David C. Seldin, Martha Skinner

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.